

Commercial**Multicentre****Accepting Site (MSHREC is NOT the reviewing HREC)****Summary of Institutional Procedures - Guide for Researchers**Queensland
GovernmentMetro South
Health**Required:**

1. All documents are to be uploaded into ERM and all submissions are via ERM.
2. This form is to be used for MSRGO guidance when the Reviewing HREC is NOT MSHREC.

Initial Submission - when a MS Site is an ACCEPTING SITE					
Document	Documents to be uploaded into ERM	Type of Letter from MSHREC	Documents to be uploaded into ERM	Type of Letter from MS RGO	Do I need to wait for the MSRGO letter?
Human Research Ethics Application +(HREA)	NA	NA	✓	Authorisation Letter All documentation submitted with the initial application for site authorisation must be noted in the Site "Authorisation to Commence Research" letter. NOTE: No RGO approval is given for the protocol. The project at the site cannot start until the RGO Authorisation Letter is issued.	Yes
Protocol			✓		
Investigator Brochure			✗		
PICF/s – Master Copy (with version control)			✓		
Assessment Tools			✓ (Only if document/s contain site specific information or identifiers)		
Patient tools eg diary, wallet card, brochures					
Advertisements			✗		
HREC Review Only Indemnity					
In addition to the items listed above, the following form part of the Site Specific Application to obtain authorisation to commence research:					
SSA Application	NA	NA	✓	Nil	No
Research Contract Approval and Study Execution Form			✓		
HREC Approval Letter			✓		
PICF/s – Site Specific (tracked only with version control)			✓		
Clinical Trial Research Agreement (CTRA)			✓		
Insurance Certificate			✓		
Site Specific Standard Indemnity			✓		
eCTN (if applicable submit as soon as received)			✓		

Commercial		Multicentre		Accepting Site (MSHREC is NOT the reviewing HREC)				
After Study Authorisation - when a MS Site is an ACCEPTING SITE								
The following documents are to be electronically uploaded into ERM.								
	Document ¹	Documents to be uploaded into ERM	Type of Letter from MSHREC	Documents to be uploaded into ERM	Type of Letter from MSRGO	Do I need to wait for the MSRGO letter?		
AMENDMENT	Protocol Amendments ² that pose NO CHANGE to the institutional risk or resource requirements	Follow Reviewing HREC's procedures	NA	✘	NA No RGO approval is given for protocol amendments	NA		
	Protocol Amendments ² that DO POSE A CHANGE to the institutional risk or resource requirements			✔	Authorisation Letter The amendment can not be implemented until MS RGO approval is given No RGO approval is given for protocol amendments	Yes		
	Research Contract Approval and Study Execution Form to accompany a protocol change that poses a risk			✔				
	HREC Approval letter of Protocol Amendment ² that DOES POSE A CHANGE to the institutional risk or resource requirements			✔				
PICF	Amended Multi-Centre Master PICF (with version control)					✔ Submit only if fulfils criteria on Page 3	Authorisation Letter Site specific PICF cannot be used until RGO Authorisation Letter is received.	Yes
	Amended Site Specific PICFs ³ (for multi-centre studies where the Master PICF is changed resulting in a significant implication for the site) (tracked only with version control)							
	HREC Approval Letter for Master PICF							
LEGAL	CTRA - amendment					✔	Signed CTRA	No
	Research Contract Approval and Study Execution Form to accompany CTRA Amendment					✔	Signed by RGO	No
	eCTN - amendment to MSRGO approved site/s					✔	NA	NA
	HREC Review Only Indemnity – amendment					✘	NA	NA
	Site Specific Standard Indemnity - amendment					✔	Signed Indemnity	No
	Updated Insurance Certificate	✔	Nil			No		
SAFETY	Investigator Brochure - update ⁴			✘	NA	NA		
	On-Site SAEs ^{4,5}			✘	✘ Site PI to submit (USMs and USADEs only)	Acknowledgement Letter	No	
	Annual Line Listings and Safety Reports ⁶			✘	NA	NA	NA	
	DSMB Reports / Letters ⁴			✘	NA	NA	NA	
	GCP Breaches ⁷ (DO NOT send deviations)			✔	Acknowledgement Letter	No		
REPORTS	Commencement Form			✘	Nil	No		
	Progress Reports (or more frequently depending on HREC approval conditions) ⁸			✔	Acknowledgement Letter	No		
	HREC Approval Letter for Progress Report			✔				
	Study or Site Closure/Suspension			✔	Nil	No		
OTHER	General correspondence (eg memos that impact on the study - eg clarification of inclusion / exclusion criteria)			✘	NA	NA		
	Change of Address of Sponsor (Australia sponsor/address only requires submission)			✔	Nil	No		
	Any other documents not listed			✔	Please check with the RGO office before submission	Nil	No	

Notations - when a MS Site is an ACCEPTING SITE

NOTATIONS

¹ Please note this document only applies to Metro South RGO as the Reviewing Institution. This Summary of Procedures document can be applied retrospectively to the 1 January 2012 to all items listed above unless the PI deems it important to notify institution (eg patient safety would be or has been compromised if institution is not notified).

² Protocol Amendments can be implemented once the CPI provides the MS's PI with the approval letter for that amendment. Examples of Risk to the Institution are new unapproved data is to be collected and/or sent off site or collection of extra tissue samples. Examples of Resource Implications are protocol requirements for extra visits or extra procedures or involvement of other departments not previously approved (eg Radiology). These examples are not an exhaustive list.

MSRGO does not approve or acknowledge protocols or protocol amendments. If the amendment requires a change to the Master PICF see '3' below as to whether it requires MSRGO approval.

³ Examples of A Significant Implication for Site at MS are protocol requirements that require a change to the CTA.

⁴ IBD, IBD updates, DSMB reports, non-MS USMs and non-MS USADE reports are not submit to MSRGO.

⁵ On-Site SAEs **are not to be submitted** to MSRGO, except if the MS PI deems the SAE is a Significant Safety Issue requiring an USM or an USADE report.

⁶ Individual Safety Reports/Letters, Quarterly, 6-Monthly and Annual Line Listings **are not to be submitted** to the MSRGO.

⁷ GCP Breaches **only are to be submitted** to both the MSHREC and MSRGO. Definition of a GCP Breach at MS is where patient safety is compromised (eg signing an unapproved PICF; enrolment of an inappropriate patient into the trial; a dosing, timing or delivery error in the study intervention attributable to members of the research team; the research team failed to comply with pre-specific trial guidelines for data collection and/or outcome evaluation due to avoidable reasons).

Deviations **are not to be submitted** to MS RGO (eg late study visits or medical or clinical assessment is missed unless patient safety is compromised, deviation that affects the ethical acceptability of the study). These examples are not an exhaustive list.

⁸ Lead site Progress Report is to be submitted to the MSRGO only if the PI deems the findings important.

GLOSSARY

Accepting PI: A Principal Investigator from an Accepting Site who is participating in the study but does not have the CPI responsibilities.

Accepting Site: A site that is participating in a multi-centre research project, but which has not taken on CPI responsibility.

Coordinating Principal Investigator (CPI): The CPI Team from the Lead Site is responsible for coordinating all HREC processes throughout the study, on behalf of the Accepting PI's over which the CPI has CPI responsibilities.

CPI: Coordinating Principal Investigator

CTRA: Clinical Trial Research Agreement

CTX: Clinical Trial Exemption

DSMB: Data Safety Monitoring Board

eCTN: Electronic Clinical Trial Notification

ERM: Ethics Research Manager

HREA: Human Research Ethics Application

HREC: Human Research Ethics Committee

Lead Site: A site that is participating in a multi-centre research project and has taken on CPI responsibility.

MS: Metro South

Multi-Centre Research: A research project undertaken by a group of institutions (or individuals) at one or more sites within and/or across Australian jurisdictions.

PI: Principal Investigator = PI for an Accepting Site in Multi-Centre Research; PI for Single-Site Research

PICF: Participant Informed Consent Form

Reviewing HREC: For multi-centre research, the reviewing HREC is NHMRC certified which, under the single ethical review process, has reviewed and ethically approved the study and has assumed responsibility for monitoring the conduct of the research being conducted at one or more sites within and/or across Australian jurisdictions. Additionally the reviewing HREC will apply the ethical review and approval process to Single-Site research at MS sites.

RGO: Research Governance Office

SAE: Serious Adverse Event

Single-Site Research: A research project undertaken at only one site.

TGA: Therapeutic Goods Administration

USADE: Unanticipated Serious Adverse Device Effect

USM: Urgent Safety Measure

REFERENCE

National Statement on Ethical Conduct in Human Research (2007) (updated 2018)

Guidance on safety monitoring and reporting in clinical trials involving therapeutic goods, November 2016

Australian Code for the Responsible Conduct of Research 2018

Framework for Monitoring: Guidance for the National Approach to Single Ethical Review of Multi-Centre Research, Jan 2012

Research Governance Handbook: Guidance for the national approach to single ethical review. December 2011

Integrated Addendum to ICH E6(R1): Guidelines for Good Clinical Practice Guidelines E6(R2) Annotated with TGA comments